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Abstract
Barth syndrome is a rare and potentially fatal X-linked disease characterized by cardiomyopathy, skeletal muscle weakness,
growth delays, and cyclic neutropenia. Patients with Barth syndrome are prone to high risk of mortality in infancy and the
development of cardiomyopathy with severe weakening of the immune system. Elamipretide is a water-soluble, aromaticcationic, mitochondria-targeting tetrapeptide that readily penetrates and transiently localizes to the inner mitochondrial membrane. Therapy with elamipretide facilitates cell health by improving energy production and inhibiting excessive formation
of reactive oxygen species, thus alleviating oxidative stress. Elamipretide crosses the outer membrane of the mitochondrion
and becomes associated with cardiolipin, a constituent phospholipid of the inner membrane. Elamipretide improves mitochondrial bioenergetics and morphology rapidly in induced pluripotent stem cells from patients with Barth syndrome and
other genetically related diseases characterized by pediatric cardiomyopathy. Data with elamipretide across multiple models
of disease are especially promising, with results from several studies supporting the use of elamipretide as potential therapy
for patients with Barth syndrome, particularly where there is a confirmed diagnosis of cardiomyopathy. This review highlights the challenges and opportunities presented in treating Barth syndrome cardiomyopathy patients with elamipretide and
addresses evidence supporting the durability of effect of elamipretide as a therapeutic agent for Barth syndrome, especially
its likely durable effects on progression of cardiomyopathy following the cessation of drug treatment and the capability of
elamipretide to structurally reverse remodel the failing left ventricle at the global, cellular, and molecular level in a gradual
manner through specific targeting of the mitochondrial inner membrane.
Keywords Elamipretide · Barth syndrome · Cardiomyopathy · Mitochondria

Introduction
Barth syndrome is a rare and potentially fatal X-linked
disease characterized by cardiomyopathy, skeletal muscle
weakness, growth delay, and cyclic neutropenia [1]. It is
caused by defects in TAZ, a gene whose product, tafazzin, is an enzyme essential for cardiolipin biosynthesis
and remodeling—cardiolipin is an integral component of
normal mitochondrial function [2–4]. Patients with Barth
syndrome are at high risk of death during infancy related to
the development of cardiomyopathy and severe weakening
of the immune system [5]. The estimated incidence of Barth
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syndrome is 1:300,000–400,000 births with 111 patients
in the USA and 230–250 globally, although the disease is
accepted as being underdiagnosed [5]. There is an unmet
need for the development of an effective therapy for patients
with Barth syndrome.
Elamipretide is a water-soluble, aromatic-cationic, mitochondria-targeting tetrapeptide that readily penetrates and
transiently localizes to the inner mitochondrial membrane
[6]. Elamipretide therapy facilitates cell health by improving energy production and inhibiting oxidative stress caused
by excessive reactive oxygen species (ROS) formation and,
as such, is a promising agent for the treatment of patients
with Barth syndrome. It targets mitochondrial dysfunction
in energy-starved myocytes, crossing the outer mitochondrial membrane and associating with cardiolipin, a key phospholipid of the inner mitochondrial membrane [7]. Elamipretide improves left ventricular ejection fraction (LVEF),
lowers left ventricular end-diastolic pressure, reduces
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cardiomyocyte and ventricular hypertrophy, limits myocardial fibrosis, and improves mitochondrial ATP-generating
capacity in animal models [8–10]. These attributes of elamipretide help position the compound as a potential therapeutic
agent targeting numerous metabolic cardiomyopathies, notably that associated with Barth syndrome.
This review highlights the challenges and opportunities presented in treating Barth syndrome and the potential
role of elamipretide. It will address the experimental evidence supporting the durability of effect of elamipretide as
a potential therapeutic agent for Barth syndrome, especially
its likely durable effects on disease progression following
the cessation of drug treatment. Finally, the review will also
address the capability of elamipretide to structurally reverse
remodel the failing left ventricle at the global, cellular, and
molecular level in a gradual temporal manner through its
specific and selective effect on the mitochondrial network.

Barth syndrome cardiomyopathy
Cardiomyopathies comprise a group of diseases that affect
the heart muscle. They are either confined to the heart or
are part of a generalized systemic myopathy disorder, both
of which often lead to cardiovascular death or progressive
heart failure-related disabilities [11]. Cardiomyopathy is
the single most frequent sign of Barth syndrome, occurring in approximately 90% of males with Barth syndrome,
although its manifestation and severity varies among individuals [12, 13]. Several cardiomyopathic phenotypes have
been described with Barth syndrome. Dilated cardiomyopathy is common and is characterized by decreased left ventricular systolic function, increased left ventricular mass,
and increased left ventricular end-diastolic and end-systolic
dimensions [12, 14, 15]. The dilated left ventricular phenotype in Barth syndrome may depend on the time course
of the disease and may emerge as a late manifestation of
disease progression. Data from the TAZPOWER trial [16]
suggest that Barth syndrome is characterized by a small left
ventricular volume consistent with restrictive cardiomyopathies and heart failure similar to that seen in young males
with Duchenne muscular dystrophy before progression to
dilation. A small left ventricular volume along with poor left
ventricular filling leading to reduced stroke volume is also
seen in patients with heart failure and preserved left ventricular ejection fraction (HFpEF). Consequently, any therapy
that targets HFpEF may also elicit improvement in patients
with Barth syndrome cardiomyopathy [16]. Left ventricular
non-compaction is also commonly seen in Barth syndrome
patients either alone or in conjunction with other cardiomyopathic phenotypes and is characterized by left ventricular
trabeculations with associated left ventricular wall motion
abnormalities [14]. Endocardial fibroelastosis may be seen,
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although less commonly [17]. Hypertrophic cardiomyopathy [18], as well as an apical form of hypertrophic cardiomyopathy [19], often characterized by small left ventricular
volumes and poor left ventricular relaxation, is also reported
to occur in Barth syndrome. A hypertrophic-dilated cardiac
phenotype, characterized by thickening of the left ventricular
walls combined with increased left ventricular mass and left
ventricular end-diastolic dimension as well as depressed left
ventricular systolic function, has also been reported [20].
Transition between distinct cardiomyopathy phenotypes
has also been described in the setting of left ventricular
non-compaction, which has been termed as an “undulating
phenotype” [21]. No current mechanism has been proposed
that explains the presence of the different cardiomyopathic
phenotypes that have been observed in Barth syndrome.
Evidence of different cardiomyopathy phenotypes is well
documented in families with recognized sarcomeric mutations, suggesting a shared molecular etiology for the different forms of cardiomyopathy [22]. Additionally, there is an
increased risk of cardiac arrhythmias in Barth syndrome,
some of which may be life-threatening. The arrhythmias
may be a direct result of abnormal mitochondrial function
[23] and/or a function of the associated cardiac phenotype,
as ventricular arrhythmias are well reported in dilated and
hypertrophic cardiomyopathies [24].
Because mitochondrial dysfunction characterized by poor
ATP production is integral to Barth syndrome and the cardiomyopathy phenotypes associated with Barth syndrome
typically manifest poor left ventricular relaxation, the relationship between ATP and left ventricular relaxation is critical in understanding the disease process. For this reason, the
importance of ATP for proper left ventricular relaxation and
filling cannot be overemphasized. It is well documented that
myocardial relaxation is an active, energy-dependent process [25]. Relaxation is typically described as having two
phases: early active relaxation and late passive relaxation.
The active relaxation during early diastole is energy (ATP)
dependent; any depletion of ATP for whatever reason will
therefore cause a slowdown in relaxation and hence poor
left ventricular filling. Passive relaxation happens late in the
diastolic phase during left atrial contraction and is dependent
on the strength of atrial contraction but, more importantly,
on compliance of left ventricular muscle. If left ventricular
wall stiffness is increased, as in the presence of myocardial
fibrosis, this phase of relaxation will not contribute to or
will contribute very little to overall left ventricular filling.
The obvious consequence of poor left ventricular filling is
reduced forward stroke output or stroke volume, a hallmark
of heart (pump) failure. It is important to note that many cardiomyopathies that occur in children and young adults can
result in left ventricular dilation. In Barth syndrome, however, it appears that the left ventricle does not dilate much
and LVEF is near normal, making most patients with this
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disease align within the defined boundaries of the HFpEF
type of left ventricular failure rather than heart failure with
reduced ejection fraction (HFrEF). In this scenario, increase
of left ventricular end-diastolic volume (EDV), as was evident after treatment with elamipretide in Barth syndrome
patients, should be viewed as a manifestation of improved
left ventricular filling and a foundation for a higher stroke
volume [25].
Left ventricular diastolic dysfunction caused by inadequate myocardial energy production occurs during myocardial ischemia at rest or following episodes of increased
energy demand states such as during exercise (Fig. 1).
There is growing and compelling evidence that most forms
of heart failure such as HFrEF or HFpEF are accompanied
by a state of energy starvation (reduced energy supply).

Abnormalities in mitochondrial ultrastructure, dynamics,
and enzymatic activities of key complexes of the electron
transfer chain (ETC) are common in the failing myocardium and are responsible, in large part, for the reduction
in ATP production [9, 26–28]. A mismatch between capillary density and cardiomyocyte hypertrophy and impaired
subendocardial perfusion due to increased left ventricular
wall stress can also contribute to an imbalance between
energy production and utilization in the failing heart.
Because myocardial contraction and relaxation are both
ATP-dependent processes, and because ATP availability is
integral to cardiomyocyte calcium-reuptake, impaired left
ventricular active relaxation and reduced left ventricular
compliance are universal features of chronic heart failure
[25].

Fig. 1  Factors affecting cardiac energy supply and demand [26].
In heart failure, the balance between cardiac demands and supply
for energy is tipped such that the supply does not meet the demand.
Inadequate myocardial energy production occurs during myocardial ischemia either at rest or following episodes of increased energy
demand, causing left ventricular diastolic dysfunction. Reduced
energy supply also accompanies HFrEF or HFpEF. Abnormalities in
mitochondrial ultrastructure, dynamics, and enzymatic activities of
key complexes of the electron transfer chain are common in the fail-

ing myocardium and are responsible, in large part, for the reduction
in ATP production. Next-generation therapies can improve on existing standard-of-care therapies by bolstering mitochondrial energy
production Adapted with permission from [26]. Abbreviations: ACEi
angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor
blocker, ETC electron transport chain, HFpEF heart failure with preserved ejection fraction, HFrEF heart failure with reduced ejection
fraction, ROS reactive oxygen species
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Mitochondrial dysfunction in heart failure
Mitochondria are double-membraned organelles that form
the energy source or the “power grid” found in nearly all
eukaryotic cells. Mitochondria function primarily to produce ATP from adenosine diphosphate (ADP), using macromolecular protein complexes that form the ETC [29].
Oxidative phosphorylation takes place along the inner
mitochondrial membrane, during which reducing equivalents, e.g., nicotinamide-adenine dinucleotide (NADH)
and reduced flavin adenine dinucleotide, are transferred
from the carrier molecules to the ETC, while protons are
pumped to the intermembrane space. Because the inner
mitochondrial membrane is impermeable to most ions and
small molecules, proton pumping generates a membrane
potential that uses ATP synthase and inorganic phosphate
to convert ADP to ATP [30, 31].
The protein complexes fixed along the mitochondrial
inner membrane include NADH dehydrogenase (complex
I), succinate dehydrogenase (complex II), cytochrome bc1
(complex III), and cytochrome c oxidase (complex IV)
[29]. The heart possesses the highest content of mitochondria of any tissue in the body [26]. It comprises about 25%
of cell volume in the human myocardium and approximately 35% of cardiomyocyte volume [29, 32, 33]. It has
been shown that mitochondria-initiated programmed cell
death or apoptosis is an important mechanism in heart
failure [34]. Mitochondrial DNA and/or ROS are triggers
of an inflammatory response in cardiac muscle [35–38].
Regulation of innate immunity by mitochondria has been
increasingly recognized in both cardiac and non-cardiac
diseases [35–39]. As sterile inflammation is common
in heart failure, mitochondria have also emerged as an
important pathogenic component. Collectively, these
observations depict molecular mechanisms promoting the
transition of mitochondria from having a purely energyproducing function to central hubs that influence cellular
survival and death.
Cellular models for Barth syndrome including patientderived fibroblasts, lymphoblasts, neutrophils, neonatal
ventricular fibroblasts, and cardiomyocytes have been
studied to reveal the morphological changes of mitochondria, the structural rebuilding of the respiratory chain, the
decreasing respiratory capacity, and the increasing production of ROS [40–43]. In order to generate a human
cellular model of Barth syndrome, somatic cells from
Barth syndrome patients were used to generate induced
pluripotent stem cells (iPSCs) with the capacity for selfrenewal and differentiation. These cell models show a
shift in the cardiolipin pool that recapitulates conditions
observed in Barth syndrome patients. Further investigation
of the iPSCs revealed that remodeling of the respiratory
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chain supercomplexes causes decreased mitochondrial
respiration and increased ROS generation [44, 45]. These
defects were also observed in cardiomyocytes generated by
directed differentiation of pluripotent stem cells [45]. The
data showed that induced stem cell-derived cardiomyocytes also recapitulated myopathic phenotypes.

Current treatment for Barth syndrome
cardiomyopathy
Treatment of cardiomyopathy in patients with Barth syndrome generally follows that for heart failure patients,
including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, beta-blockers, and/or
diuretics according to the particular heart failure phenotype
[19]. Oral anticoagulation should be considered if appropriate [1]. Prostaglandin E
 1 may be beneficial with right ventricular failure [46]. Heart transplantation can be considered
if heart failure treatment is ineffective [47–50] and bridging
mechanical circulatory support can be used until transplantation becomes available [51].

Elamipretide
A more logical approach to the treatment of Barth syndrome
cardiomyopathy is to target the underlying mitochondrial
pathology of Barth syndrome that precipitates the cardiomyopathy. Elamipretide is being investigated as such an
approach.
Elamipretide is a water-soluble, aromatic-cationic, mitochondria-targeting tetrapeptide that readily penetrates and
transiently localizes to the inner mitochondrial membrane
where it associates with cardiolipin. Elamipretide improves
inner membrane stability, protein–protein interactions, and
ATP production, and reduces pathogenic ROS production.
Cardiolipin plays an integral role in cristae formation, mitochondrial fusion, mitochondrial DNA stability and segregation, and organization of the respiratory complexes into
supercomplexes for oxidative phosphorylation [52–56].
Elamipretide has been shown to enhance ATP synthesis
in multiple organs and tissues, including the heart, kidney,
neurons, and skeletal muscle [9, 52–55, 57]. High-resolution respirometry of ETC complexes in permeabilized ventricular fibers from ischemia–reperfusion rats showed that
ischemia–reperfusion-induced decrements in mitochondrial
complexes I, II, and IV were significantly alleviated with
elamipretide [58]. Furthermore, studies in serial block-face
scanning electron microscopy used to create high-resolution 3-dimensional reconstructions of cristae ultrastructure
showed that disease-induced fragmentation of cristae networks was improved with elamipretide [58]. Studies using
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biomimetic membranes modeling of the inner mitochondrial
membranes also showed that elamipretide improved mitochondrial inner membrane biophysical properties by aggregating cardiolipin [58]. Importantly, the elamipretide effect
of improving membrane integrity was even observed when
cardiolipin levels in the in vitro system were lowered to levels consistent with those seen in Barth syndrome [58]. Furthermore, the elamipretide-mediated effects on membranes
were observed across independent model systems where cardiolipin was oxidized or enriched with monolysocardiolipin,
the immature form of cardiolipin found in Barth syndrome
[57, 59]. These studies suggest that mitochondrial structure
and function are, as expected, interdependent and demonstrate that elamipretide targets mitochondrial membranes to
stabilize cristae networks and improves bioenergetic function [58].
Elamipretide has been shown to improve mitochondrial bioenergetics and morphology rapidly (within hours
or days) in iPSCs from Barth syndrome and other closely
related pediatric cardiomyopathies [60, 61]. Re-establishing
appropriate energy supply–demand balance (Fig. 1) leads to
a restoration of healthy gene expression (within days) and
improved cardiac and mitochondrial protein turnover (within
weeks) [26, 62]. Many mitochondrial functions, including
oxidative phosphorylation, are strongly associated with the
inner mitochondrial membrane [59]. The abnormal structure and function of the mitochondrial network is reflected
by impaired mitochondrial cristae structure and loss of
mitochondrial network connectivity. Elamipretide has been
shown by electron and fluorescence microscopy to restore
this architecture in compromised mitochondria, resulting in
improved cellular bioenergetics [58]. Studies using Barth

syndrome patient-derived cell lines and iPSC-derived, beating cardiomyocytes from pediatric patients with cardiomyopathy showed that elamipretide also restores this architecture
in compromised mitochondria, leading to improvements in
overall cellular function [59]. Furthermore, in cells engineered using CRISPR to have a TAZ mutation, the decline
seen in several different ETC subunits and altered mitochondrial quality control was attenuated after 7 days of elamipretide treatment in vitro [63].

Preclinical studies of elamipretide on cardiac
function in heart failure
A murine model of Barth syndrome has been developed [6];
however, the effects of elamipretide on cardiac function in
heart failure in this model have not been reported. Elamipretide has been studied extensively in models of experimental left ventricular dysfunction and heart failure (Table 1).
These studies in animal models of experimental heart failure
provide much of the knowledge base available to date that
supports the potential use of elamipretide for the treatment
of patients with cardiomyopathies as in Barth syndrome.
Elamipretide reverses SERCA2a maladaptations
and ameliorates inflammatory markers in heart failure
Abnormal sarcoplasmic reticulum calcium cycling is a
key characteristic of the failing heart along with a sustained increase of circulating levels of pro-inflammatory
cytokines. These maladaptations can be viewed as resulting from biochemical alterations to cellular and molecular
signaling pathways that result from the chronic heart failure

Table 1  Summary of key preclinical studies of elamipretide in heart failure
Reference

Model

Results

Elamipretide (3 months) improved LVEF and indices of LV diastolic function, normalized plasma
Sabbah et al. [9] Canine model of
biomarkers (nt-proBNP, TNF-a, and CRP), SERCA2a activity, COX1 and ND1 DAMPs, and
microembolizationreversed mitochondrial abnormalities (respiration, ∆φm, maximum ATP synthesis rate, and ATP/
induced advanced HF
ADP ratio) in LV myocardium compared to placebo
Eirin et al. [8]
Porcine model of reno- Elamipretide (3 months) normalized mitochondrial respiration, mitochondrial calcium tolerance and
permeability pore opening, mitochondrial membrane potential, SERCA2a activity, maximum of
vascular hypertension
ATP synthesis rate, and mitochondrial complex I and IV activities, reduced ROS formation and
manifesting HFpEF
cytochrome c release into the cytosolic compartment. Left ventricular relaxation was improved and
cardiomyocyte hypertrophy reduced
Chiao et al. [64] Old mice
Elamipretide (8 weeks) normalized diastolic functional deficit, increased Ea/Aa, and improved exercise tolerance with regression of cardiac hypertrophy accompanied by normalization of mitochondrial proton leak and ROS
ADP adenosine diphosphate, CRP C-reactive protein, DAMP DNA damage-associated molecular patterns, Ea/Aa early-to-late diastolic mitral
annulus velocities, HF heart failure, HFpEF heart failure with preserved ejection fraction, LV left ventricle, LVEF left ventricular ejection fraction, nt-pro-BNP n-terminal pro-brain natriuretic peptide, ROS reactive oxygen species, SERCA2a sarco-/endoplasmic reticulum Ca2+ ATPase,
TNF-a tumor necrosis factor-a, ∆φm membrane potential
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state. Reversal of these abnormalities often requires longterm therapy capable of restoring aberranul cellular and
molecular signaling. In a murine model of Barth syndrome,
myocardial sarco-/endoplasmic reticulum C
 a2+ ATPase
(SERCA2a) activity was impaired and SERCA2a tyrosine
nitration increased compared to wild-type mice [6]. A reduction in SERCA2a activity and expression often leads to poor
left ventricular active relaxation and overall left ventricular
diastolic dysfunction. In Barth syndrome patients with SERCA2a, expression is often reduced [4] and patients nearly
always manifest left ventricular diastolic dysfunction [10].
These findings suggest that SERCA2a abnormalities may be
overcome by therapies that target cardiolipin deficiency typically observed in patients with Barth syndrome, particularly
those manifesting HFpEF.
In a canine model of HFrEF, SERCA2a activity and
protein levels were shown to be significantly decreased in
the left ventricular myocardium compared to normal dogs
but were normalized after long-term treatment with elamipretide [9]. The improvement in SERCA2a was accompanied by improved indexes of left ventricular diastolic function. Plasma levels of cytokines (tumor necrosis factor-α
and interleukin-6) and C-reactive protein are significantly
elevated compared to normal baseline levels in dogs with
microembolization-induced heart failure [9]. Long-term
(3 months) treatment with elamipretide normalized all
three of these elevated factors in this heart failure model
[9]. Plasma mitochondrial DNA damage-associated molecular patterns (DAMPs), specifically within the COX1 and
ND1 genes, are markedly elevated in dogs with heart failure
compared to normal. Long-term treatment with elamipretide
normalized plasma levels of both COX1 and ND1 DAMPs
in this model [4]. These observations of long-term therapy
suggest that elamipretide is capable of reversing abnormal
cellular and molecular signaling that gradually develops during the development of the heart failure state.
The effects of elamipretide on diastolic left ventricular
function have also been examined in a porcine model of
renovascular hypertension that manifests HFpEF, as evidenced by preserved LVEF, left ventricular hypertrophy,
poor left ventricular relaxation, reduced SERCA2a activity
and expression, and reduced phospholamban phosphorylation at serine 16 [8]. Long-term (3 months) therapy with
elamipretide normalized mitochondrial respiration; mitochondrial calcium tolerance and permeability pore opening;
mitochondrial membrane potential; calcium ATPase activity
(SERCA2a); maximum rate of ATP synthesis; mitochondrial
complex I and IV activities; reduced cytochrome c release
into the cytosolic compartment; and reduced ROS formation. Left ventricular relaxation was improved and cardiomyocyte hypertrophy reduced. These results support the use
of elamipretide as a potential therapy for patients with Barth
syndrome that manifest a HFpEF phenotype.
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Durability of action of elamipretide
Therapeutic compounds such as beta-blockers or ACE
inhibitors are considered to have “durable effects” in heart
failure if the elicited benefits remain evident and dissipate
only gradually, within days or weeks, after the withdrawal
of therapy. Stated differently, durability reflects sustained
pharmacodynamic functional benefits that outlast the pharmacokinetic elimination of the compound. This is in contrast to therapeutic compounds such as the beta1-receptor
agonist, dobutamine, whereby the elicited benefits dissipate
rapidly, often within minutes of withdrawal of therapy. This
therapeutic durability on the heart and circulation is often
ascribed to a compound the property, during its chronic use,
that actively elicits structural, functional, and biochemical
benefits which could potentially alter disease trajectory.
In a canine model of chronic heart failure, a single dose of
elamipretide resulted in favorable changes in left ventricular
fractional shortening that took nearly 7 days to dissipate following dosing, i.e., beyond the 4-h half-life of elamipretide
(Fig. 2) [Sabbah, personal observation]. Furthermore, in
old (24 months of age) mice with left ventricular diastolic
dysfunction as evidenced by a reduced ratio of early-to-late
diastolic mitral annulus velocities (Ea/Aa) and an increased
(poorer) myocardial performance index, an 8-week treatment with elamipretide normalized the diastolic functional
deficit with an increase in Ea/Aa [64]. The improvement
of diastolic function was associated with normalization of
mitochondrial proton leak, reduced mitochondrial ROS, and
reduced protein oxidation overall as well as at the cellular
level. In these old mice, exercise tolerance on a treadmill
running test was also improved with elamipretide, and a
regression of age-related cardiac hypertrophy was observed
at necropsy. To evaluate the durability of the elamipretideinduced cardiac benefit, cardiac function was monitored for
4 weeks after the end of treatment. An improvement of Ea/
Aa was maintained for up to 2 weeks after withdrawal of
elamipretide but dropped by approximately 50% 4 weeks
after treatment was stopped (Fig. 3) [64].
Whereas drug withdrawal–type studies, such as those
described above, are very helpful in addressing issues related
to the “durable effects” of a given cardioactive drug, they
are not always possible or appropriate as part of translational
preclinical studies or clinical trials. Nonetheless, supportive
evidence for establishing the potential of “durable effects”
of a cardioactive drug can be ascertained through understanding the mechanism of action of the drug in question.
Elamipretide, for instance, selectively targets the mitochondria and directly impacts function of the inner mitochondrial
membrane through its association with cardiolipin. This
action of elamipretide directly improves myocardial energetics but does not have any direct effects on left ventricular
remodeling at the global or cellular levels. Nevertheless,
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Fig. 2  Durability of left ventricular function following a single
dose of elamipretide in failing
canine hearts [Sabbah personal
observation]. In a canine model
of chronic heart failure, a single
dose of elamipretide resulted
in favorable changes in left
ventricular fractional area of
shortening, the effect of which
took 7 days to completely
disappear (i.e., beyond the
4-h half-life of elamipretide).
Abbreviation: FAS, fractional
area of shortening

it has been previously shown that long-term monotherapy
with elamipretide in a canine model of chronic heart failure,
through its action on mitochondria, also leads to improved
left ventricular systolic and diastolic function and prevention of progressive left ventricular enlargement [9]. The
magnitude of improvement was similar to that observed in
the same canine heart failure model after long-term therapy
with ACE inhibitors and/or beta-blockers [65]. These benefits occurred alongside normalization of mitochondrial

function as evidenced by an improved rate of ATP synthesis and reduced ROS formation. These improvements in
histomorphometric measures of left ventricular structural
remodeling observed after treatment with elamipretide are
similar in magnitude to those seen in this canine heart failure
model after monotherapy with ACE inhibitors, angiotensin II receptor blockers, and beta-blockers [65–68] and are
not likely to immediately subside if elamipretide therapy is
withdrawn.

Fig. 3  Durability of elamipretide-induced cardiac benefit
in mice with diastolic dysfunction [62]. In old mice with LV
diastolic dysfunction, treatment
with elamipretide for 8 weeks
normalized diastolic functional
deficit, as evidenced by an
increase in Ea/Aa. Improvement in diastolic function was
associated with normalization
of mitochondrial proton leak,
reduced mitochondrial ROS,
and reduced protein oxidation
overall as well as at the cellular
level. Exercise tolerance also
improved. Ea/Aa improvement was maintained for up
to 2 weeks after withdrawal of
elamipretide. Used with permission from [62]. Abbreviations:
Ea/Aa ratio of early-to-late diastolic mitral annulus velocities,
ROS reactive oxygen species
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Fig. 4  Time course of cardiac
changes following treatment
with elamipretide [56]. Chronic
therapy with elamipretide,
which selectively targets abnormal mitochondrial function of
the failing heart, can ultimately
lead to durable functional and
structural improvements of the
left ventricle as a whole. Used
with permission [56]

Elamipretide has also been shown to elicit structural
improvement to mitochondria and its constituents that are
not likely to immediately dissipate upon withdrawal of
elamipretide. The improvement in mitochondrial function
following long-term therapy with elamipretide leads to normalization of the mitochondrial inner membrane structure
and function, including normalization of cardiolipin and the
enzymes responsible for its synthesis and remodeling, and
normalization of activities of the various ETC complexes
[4, 9, 27]. Normalization of cardiolipin plays an important
role in cristae formation, activity of respiratory complexes,
organization of the respiratory complexes into supercomplexes for oxidative phosphorylation, mitochondria fusion,
and mitochondria DNA stability and segregation [69–72].
Again, these beneficial corrections of mitochondrial structural and functional components are not likely to rapidly
dissipate upon withdrawal of elamipretide therapy [71, 73].
Studies in non-cardiac models of disease also support the
notion that chronic therapy with elamipretide has “durable
organ structural effects.” In rats exposed to 45 min of bilateral renal ischemia and followed for 1 month, glomerular
and peritubular capillary rarefaction, macrophage infiltration, fibrosis, mitochondrial degeneration, mitophagy, and
deformed foot processes in podocytes were observed. When
rats were then treated with elamipretide for 6 weeks (i.e.,
starting 1 month after ischemia), elamipretide preserved
mitochondrial integrity, restored glomerular capillaries and
podocyte structure, and attenuated glomerulus sclerosis and
interstitial fibrosis [74].
Sequence of biological events leading to amelioration
of left ventricular remodeling
There is a good scientific basis for the rationale that
chronic therapy with a drug, such as elamipretide, that
selectively targets abnormal mitochondrial function of the
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failing heart can ultimately lead to durable functional and
structural improvements of the left ventricle as a whole
(Fig. 4) [58]. In the case of the failing or cardiomyopathic
heart, improvement of mitochondrial function can occur
within hours or days of initiating elamipretide therapy
[60, 61]. This rapid improvement in myocardial energetics
can, within days or weeks, lead to improved expression of
key genes that trigger the synthesis of proteins essential to
the recovery of mitochondria and cardiomyocyte toward a
more normal phenotype.
Table 2  Baseline demographic and clinical characteristics of Barth
syndrome patients enrolled in the TAZPOWER Trial [16]
Characteristic

Value

Mean age, y (range)
Male, n (%)
Race, n (%)
White
Multiracial
Ethnicity, n (%)
Not Hispanic or Latino
Hispanic or Latino
Mean height, cm (range)
Mean weight, kg (range)
BMI, kg/m2 (range)
6MWT, m
Mean BTHS-SA total fatigue score
Mean 3D LVEDV, Z-score (SD)
Mean 3D LVSV, Z-score (SD)
Mean EF, % (SD)

19.5 (12–35)
12 (100)
11 ()
1 ()
12 (100)
0
167.3 (150.4–187.7)
50.8 (31.4–85.9)
17.6 (13.6–24.4)
395.5
8
–2 (1.34)
–1.84 (1.53)
60.6 (4.0)

Used with permission from [Thompson et al. 16]
6MWT 6-min walk test, BTHS-SA Barth Syndrome Symptom Assessment scale, BMI body-mass index, EF ejection fraction, LVEDV left
ventricular end-diastolic volume, LVSV left ventricular stroke volume,
SD standard deviation, y year
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Fig. 5  Flow of Barth syndrome
patients in the TAZPOWER
(SPIBA-201) Trial [16]. Used
with permission from [16]

In dogs with heart failure, for instance, chronic (3 months)
treatment with elamipretide resulted in normalized expression of proteins involved in key pathways such as SERCA2a,
peroxisome proliferator-activated receptor co-activator-1α,
mitochondrial fission and fusion, cardiolipin synthesis and
remodeling, and mitochondria cristae formation among
others [9, 27]. Because proper protein turnover in mitochondria and cardiomyocytes requires weeks and possibly
months [68], the expectation for restoration of near-normal
mitochondria and cardiomyocyte structure and function will
occur weeks or even months after initiating therapy. Only
then can one expect a drug such as elamipretide to show benefits in preventing or reversing left ventricular remodeling
or in improving exercise tolerance in patients with chronic
heart failure.
In dogs with chronic heart failure (3 months), therapy
with elamipretide resulted in the prevention of progressive
left ventricular remodeling evidenced by prevention of progressive left ventricular dilation globally, and by reduced
cardiomyocyte hypertrophy and interstitial fibrosis and
by increased capillary density at the cellular level [9]. As

alluded to earlier, these structural changes of the left ventricular chamber and left ventricular myocardium are similar
to those seen in the same dog model of heart failure after
chronic therapy with an ACE inhibitor, an angiotensin II
receptor blocker, or a beta-blocker, and are part and parcel of
the acknowledged durability of these drugs in heart failure.

Treating Barth syndrome with elamipretide: clinical
insights from the TAZPOWER trial
TAZPOWER is a phase 2, randomized, double-blind, placebocontrolled, crossover trial of elamipretide followed by a longterm, open-label treatment extension of elamipretide in patients
with genetically confirmed Barth syndrome [16]. The controlled
part of the study is complete, while the long-term extension is
ongoing. TAZPOWER was designed to evaluate the efficacy
and safety of elamipretide in patients with Barth syndrome.
Twelve patients (mean age 19.5 years, range 12–35 years) with
genetically confirmed Barth syndrome were initially enrolled.
The baseline demographic and clinical characteristics of this
population are summarized in Table 2. The cardiac phenotype
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of these patients was hypertrophic cardiomyopathy characterized by lower-than-normal left ventricular end-diastolic and
end-systolic volumes, and normal LVEF with reduced stroke
volume. In the initial, controlled part of the trial, patients were
randomized to once-daily subcutaneous injection of elamipretide
40 mg or placebo for 12 weeks followed by crossover to the
alternate treatment after a 4-week washout. In the second part
of trial, ten of the 12 patients continued to receive subcutaneous
elamipretide 40 mg once daily for up to an additional 168 weeks:
eight of the ten patients have completed an additional 36 weeks’
treatment during the open-label extension. A flow chart for
patient participation in the trial is shown in Fig. 5.
There were no statistically significant improvements in
primary and secondary study endpoints after 12 weeks’
treatment with elamipretide compared to placebo. However,
there were statistically significant improvements compared
to baseline after completion of 36 weeks’ treatment with
elamipretide during the open-label extension (i.e., a total
of 48 weeks’ treatment). There was a significant (p = 0.020)
increase of 95.9 m in 6-min walking time, which was equivalent to a 25% improvement. Additional outcome measures
showed improvement at week 36 of the open-label extension including Barth Syndrome Symptom Assessment
total fatigue scale score (p = 0.030) and muscle strength by
hand-held dynamometry (p = 0.001). Cardiac function was
also determined by echocardiography. Cardiac dysfunction
has been shown to be a primary cause of early mortality in
patients with Barth syndrome and improvements in LVEDV
and left ventricular stroke volume are major determinants of
peak exercise capacity in patients with hypertrophic cardiomyopathy. Elamipretide treatment provided a 16% improvement in average left ventricular stroke volume indexed to
body surface area from baseline (30.5 ml/m2) to the end of
the open-label extension (35.3 ml/m2). There was a significant (p < 0.01) trend of an increase in stroke volume over
time using a slope model of individual regression lines for
each patient to determine the consistent change in stroke volume index over the course of exposure. Mean stroke volume
Z-scores increased from − 1.38 at baseline to − 5.6 at week
36 of the open-label extension.
Elamipretide was generally well tolerated with the majority of adverse events being mild to moderate in severity.
The majority of adverse events were injection site reactions,
including erythema, pain, and pruritus. Two patients discontinued during the open-label extension because of injection
site reactions.

Conclusions
Elamipretide has been shown to improve myocardial
energetics through its direct action on the mitochondrial
inner membrane through its association with cardiolipin.
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Multiple studies have shown that the improvement in myocardial energetics as a result of therapy with elamipretide
elicits long-term improvements of left ventricular systolic
and diastolic function, and, importantly, a prevention or
reversal of maladaptive global and cellular left ventricular
chamber remodeling. Promising results with elamipretide
across various animal models of heart disease are especially encouraging for heart failure and cardiomyopathies
in general, including Barth syndrome. Long-term therapy
with elamipretide not only normalizes mitochondrial ultrastructure, dynamics (fission and fusion), and function but
also appears to have a positive residual lasting footprint
on the heart failure/cardiomyopathic phenotype that goes
beyond myocardial energetics. Indeed, the benefits extend
to improvements of myocardial structure and function that
are durable and not likely to immediately dissipate upon
withdrawal of therapy. The US Food and Drug Administration has granted Fast Track and Orphan Drug designations
for elamipretide in the treatment of patients with Barth
syndrome. The clinical results seen in patients with Barth
syndrome treated with elamipretide support the potential
use of this drug for the clinical management of this rare
disease syndrome [16].
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